4.6 Review

Genomics of hypertension: the road to precision medicine

Journal

NATURE REVIEWS CARDIOLOGY
Volume 18, Issue 4, Pages 235-250

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41569-020-00466-4

Keywords

-

Funding

  1. Medical Research Council [MR/M016560/1]
  2. British Heart Foundation [PG/12/85/29925, CS/16/1/31878, RE/18/6/34217]
  3. Health Data Research UK
  4. Chief Scientist Office, Scotland
  5. UK Research and Innovation Strength in Places Fund (SIPF) [35049]
  6. British Heart Foundation [PG/12/85/29925, CS/16/1/31878] Funding Source: researchfish
  7. Medical Research Council [MR/M016560/1] Funding Source: researchfish

Ask authors/readers for more resources

The genetic architecture of blood pressure is complex, involving multiple genes and SNPs, but currently only explains a portion of its heritability. Studying blood pressure syndromes may help to better understand the biological mechanisms of the disease.
The known genetic architecture of blood pressure now comprises >30 genes, with rare variants resulting in monogenic forms of hypertension or hypotension and >1,477 common single-nucleotide polymorphisms (SNPs) being associated with the blood pressure phenotype. Monogenic blood pressure syndromes predominantly involve the renin-angiotensin-aldosterone system and the adrenal glucocorticoid pathway, with a smaller fraction caused by neuroendocrine tumours of the sympathetic and parasympathetic nervous systems. The SNPs identified in genome-wide association studies (GWAS) as being associated with the blood pressure phenotype explain only approximately 27% of the 30-50% estimated heritability of blood pressure, and the effect of each SNP on the blood pressure phenotype is small. A paucity of SNPs from GWAS are mapped to known genes causing monogenic blood pressure syndromes. For example, a GWAS signal mapped to the gene encoding uromodulin has been shown to affect blood pressure by influencing sodium homeostasis, and the effects of another GWAS signal were mediated by endothelin. However, the majority of blood pressure-associated SNPs show pleiotropic associations. Unravelling these associations can potentially help us to understand the underlying biological pathways. In this Review, we appraise the current knowledge of blood pressure genomics, explore the causal pathways for hypertension identified in Mendelian randomization studies and highlight the opportunities for drug repurposing and pharmacogenomics for the treatment of hypertension. In this Review, Padmanabhan and Dominiczak discuss how genomics has transformed our understanding of blood pressure regulation and hypertension, summarizing the current knowledge of blood pressure genomics and highlighting the opportunities and challenges for drug repurposing and pharmacogenomics for the treatment of hypertension.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available